beta1-adrenoceptor polymorphism predicts flecainide action in patients with atrial fibrillationbeta1-adrenoceptor多态性预测房颤患者氟卡尼行动.pdfVIP

Beta -Adrenoceptor Polymorphism Predicts Flecainide 1 Action in Patients with Atrial Fibrillation 1. 1. 1. 1 1 Amir M. Nia , Evren Caglayan , Natig Gassanov , Tom Zimmermann , Orhan Aslan , Martin 2 3 1 1 1 Hellmich , Firat Duru , Erland Erdmann , Stephan Rosenkranz , Fikret Er * 1 Department of Internal Medicine III, University of Cologne, Cologne, Germany, 2 Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne, Germany, 3 Clinic for Cardiology, University Hospital Zurich, Zurich, Switzerland Abstract Background: Antiarrhythmic action of flecainide is based on sodium channel blockade. Beta -adrenoceptor (b AR) 1 1 activation induces sodium channel inhibition, too. The aim of the present study was to evaluate the impact of different b1AR genotypes on antiarrhythmic action of flecainide in patients with structural heart disease and atrial fibrillation. Methodology/Principal Findings: In 145 subjects, 87 with atrial fibrillation, genotyping was performed to identify the individual b1AR Arg389Gly and Ser49Gly polymorphism. Resting heart rate during atrial fibrillation and success of flecainide- induced cardioversion were correlated with b1AR genotype. The overall cardioversion rate with flecainide was 39%. The Arg389Arg genotype was associated with the highest cardioversion rate (55.5%; OR 3.30; 95% CI; 1.34–8.13; p = 0.003) compared to pat